By: Benzinga
Piper Jaffray Reiterates Neutral Rating, $10 PT on ISIS Pharmaceuticals
In a report published Monday, Piper Jaffray & Co. reiterated its Neutral rating and $10.00 price target on ISIS Pharmaceuticals (NASDAQ: ISIS ). Piper Jaffray noted, “This morning, ISIS signed a new antisense collaboration with Biogen Idec (BIIB) for 3 undisclosed neurological and neuromuscular targets. Although the deal brings in
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here